234 related articles for article (PubMed ID: 19527192)
1. Ceftobiprole: a new broad spectrum cephalosporin.
El Solh A
Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
[TBL] [Abstract][Full Text] [Related]
2. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Anderson SD; Gums JG
Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
[TBL] [Abstract][Full Text] [Related]
3. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
4. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
5. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
[TBL] [Abstract][Full Text] [Related]
6. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
8. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
Noel GJ
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
[TBL] [Abstract][Full Text] [Related]
9. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Vidaillac C; Rybak MJ
Pharmacotherapy; 2009 May; 29(5):511-25. PubMed ID: 19397461
[TBL] [Abstract][Full Text] [Related]
10. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.
Schirmer PL; Deresinski SC
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):777-91. PubMed ID: 19735220
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials.
Deresinski SC
Diagn Microbiol Infect Dis; 2008 May; 61(1):103-9. PubMed ID: 18384998
[TBL] [Abstract][Full Text] [Related]
12. New and emerging treatment of Staphylococcus aureus infections in the hospital setting.
Moreillon P
Clin Microbiol Infect; 2008 Apr; 14 Suppl 3():32-41. PubMed ID: 18318877
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model.
Arias CA; Singh KV; Panesso D; Murray BE
J Antimicrob Chemother; 2007 Sep; 60(3):594-8. PubMed ID: 17606481
[TBL] [Abstract][Full Text] [Related]
15. Ceftobiprole: a new beta-lactam antibiotic.
Stein RA; Goetz RM; Ganea GM
Int J Clin Pract; 2009 Jun; 63(6):930-43. PubMed ID: 19490203
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
Lodise TP; Patel N; Renaud-Mutart A; Gorodecky E; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):96-102. PubMed ID: 18384996
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action and antimicrobial activity of ceftobiprole.
Morosini MI; Díez-Aguilar M; Cantón R
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):3-10. PubMed ID: 31364335
[TBL] [Abstract][Full Text] [Related]
18. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
Arias CA; Singh KV; Panesso D; Murray BE
Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
[TBL] [Abstract][Full Text] [Related]
19. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
Scheeren TW
Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
[TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
Lascols C; Legrand P; Mérens A; Leclercq R; Muller-Serieys C; Drugeon HB; Kitzis MD; Reverdy ME; Roussel-Delvallez M; Moubareck C; Brémont S; Miara A; Gjoklaj M; Soussy CJ
Int J Antimicrob Agents; 2011 Mar; 37(3):235-9. PubMed ID: 21295447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]